Vimarsana
Biggest News Aggregation in the World

Page 5 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis - Vimarsana News

Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.

Positive Phase 3 Results Announced for Nemolizumab Treatment of Atopic Dermatitis, Prurigo Nodularis - Vimarsana News

Positive Phase 3 Results Announced for Nemolizumab Treatment of Atopic Dermatitis, Prurigo Nodularis

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy - Vimarsana News

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...

Arcutis Announces Supplemental New Drug Application of Roflumilast for Atopic Dermatitis in Adults, Children - Vimarsana News

Arcutis Announces Supplemental New Drug Application of Roflumilast for Atopic Dermatitis in Adults, Children

The sNDA was announced for roflumilast cream 0.15% to the FDA, and the formulation is said to not to be disruptive to the skin barrier or contain common irritants to patients’ skin.

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th - Vimarsana News

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...